Cabozantinib for Castration-Resistant Prostate Cancer

Cabozantinib is a multiple tyrosine kinase inhibitor that blocks the vascular endothelial growth factor receptor (VEGFR) and the receptor of hepatocyte growth factor (C-MET), resulting in significant benefits for patients with metastatic prostate cancer. Increases in MET occurs after selective anti-VEGF therapy and constitutes a mechanism of acquired or evasive resistance to agents that target VEGF signalling. In this study, 85% of patients achieved either complete or partial resolution of metastatic bone tumors and 67% of patients achieved tumor shrinkage of  liver and lung metastasis. The median progression-free survival (PFS) was significantly longer for patients on cabozantinib (21 weeks) compared with 6 weeks for the placebo. The overall survival has not yet been achieved. I like this drug because unlike previous inhibitors of angiogenesis, it simultaneously targets MET and VEGFR2, which together are involved in the development and progression of many cancers.
Cabozantinib Shows Unprecedented Activity in Patients with Castration-resistant Prostate Cancer.

Speak Your Mind